A robust deal-making market has enabled gene therapy drug development to be advanced and adequately funded through alliances and financings, and in many cases has provided exits for investors through acquisitions. The volume of deals in each of these transaction types has experienced some fluctuation during 2012–17, but generally is on an upward trend as companies aim to capitalize on a market that has been reinvigorated with the strong scientific and commercial argument for cell and gene therapies, particularly chimeric antigen receptor T-cell (CAR-T) therapies.
Among acquisitions, there was virtually an even split between targets focused on in vivo gene therapies, or gene therapies, and those concentrating on ex vivo cell and gene therapies. However, large pharmaceutical buyers were more likely to acquire in vivo therapy developers, reflective more of the disease focus of the target company rather than the overall gene therapy development strategies of the acquirers. Alliances, too, did not show a preference for one approach over the other, but gene therapy companies were more active in aggregate financing than cell and gene therapy players, possibly an effect of the emergence only within the last few years of start-ups founded around CAR-T and other cell and gene therapies.
The broad field of gene therapy may be broken down into two main categories: gene therapy, which mainly involves the in vivo administration of genes, packaged into viral or non-viral vectors, directly into cells inside of the body; or cell and gene therapy, which comprises the ex vivo genetic modification of cells. Certain datasets within the report are split in this manner.
The sources of the deals data throughout the report are the authors Medtrack and Strategic Transactions.
Among acquisitions, there was virtually an even split between targets focused on in vivo gene therapies, or gene therapies, and those concentrating on ex vivo cell and gene therapies. However, large pharmaceutical buyers were more likely to acquire in vivo therapy developers, reflective more of the disease focus of the target company rather than the overall gene therapy development strategies of the acquirers. Alliances, too, did not show a preference for one approach over the other, but gene therapy companies were more active in aggregate financing than cell and gene therapy players, possibly an effect of the emergence only within the last few years of start-ups founded around CAR-T and other cell and gene therapies.
The broad field of gene therapy may be broken down into two main categories: gene therapy, which mainly involves the in vivo administration of genes, packaged into viral or non-viral vectors, directly into cells inside of the body; or cell and gene therapy, which comprises the ex vivo genetic modification of cells. Certain datasets within the report are split in this manner.
The sources of the deals data throughout the report are the authors Medtrack and Strategic Transactions.
Table of Contents
EXECUTIVE SUMMARY
GENE THERAPY DEAL-MAKING ACROSS THE INDUSTRY
GENE THERAPY ACQUISITIONS
GENE THERAPY ALLIANCES
GENE THERAPY FINANCINGS
DEAL-MAKING CASE STUDIES IN GENE THERAPY
APPENDIX
LIST OF FIGURES
LIST OF TABLES
Companies Mentioned
- Pfizer
- Vertex
- Biogen
- Bamboo Therapeutics
- Gilead